10-Q Filing

GUARDANT HEALTH, INC. CIK: 1576280 Q2 2022

Filing Information

Form Type	10-Q
Accession Number	`0001576280-22-000058`
Period End Date	20220630
Filing Date	20220804
Fiscal Year	2022
Fiscal Period	Q2
XBRL Instance	gh-20220630_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 86 Income Statement 96 Cash Flow Statement 95 Stockholders Equity 44 Comprehensive Income 28

Balance Sheet 86 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$938.59M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$215.17M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$492.20M	USD	Point-in-time
Short-term marketable securities	`MarketableSecuritiesCurrent`	$440.55M	USD	Point-in-time
Short-term marketable securities	`MarketableSecuritiesCurrent`	$638.52M	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$95.28M	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$97.65M	USD	Point-in-time
Preferred stock, par value (in usd per share)	`PreferredStockParOrStatedValuePerShare`	-	USD	Point-in-time
Preferred stock, par value (in usd per share)	`PreferredStockParOrStatedValuePerShare`	-	USD	Point-in-time
Inventory	`InventoryNet`	$59.89M	USD	Point-in-time
Inventory	`InventoryNet`	$30.67M	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Prepaid expenses and other current assets, net	`PrepaidExpenseAndOtherAssetsCurrent`	$28.28M	USD	Point-in-time
Prepaid expenses and other current assets, net	`PrepaidExpenseAndOtherAssetsCurrent`	$53.05M	USD	Point-in-time
Preferred stock issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Total current assets	`AssetsCurrent`	$1.11B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$1.04B	USD	Point-in-time
Long-term marketable securities	`MarketableSecuritiesNoncurrent`	$382.57M	USD	Point-in-time
Preferred stock outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Long-term marketable securities	`MarketableSecuritiesNoncurrent`	$698.03M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$124.46M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$163.36M	USD	Point-in-time
Common stock, par value (in usd per share)	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Common stock, par value (in usd per share)	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Right-of-use assets, net	`OperatingLeaseRightOfUseAsset`	$183.70M	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Right-of-use assets, net	`OperatingLeaseRightOfUseAsset`	$189.44M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$14.21M	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	101.77M	shares	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	102.19M	shares	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$13.11M	USD	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	102.19M	shares	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	101.77M	shares	Point-in-time
Goodwill	`Goodwill`	$3.29M	USD	Point-in-time
Goodwill	`Goodwill`	$3.29M	USD	Point-in-time
Other assets, net	`OtherAssetsNoncurrent`	$60.94M	USD	Point-in-time
Assets	`Assets`	$1.85B	USD	Point-in-time
Other assets, net	`OtherAssetsNoncurrent`	$70.56M	USD	Point-in-time
Assets	`Assets`	$2.20B	USD	Point-in-time
Liabilities	`Liabilities`	$1.53B	USD	Point-in-time
Total Assets	`Assets`	$1.85B	USD	Point-in-time
Liabilities	`Liabilities`	$1.56B	USD	Point-in-time
Total Assets	`Assets`	$2.20B	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$17.58M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$36.97M	USD	Point-in-time
Accrued compensation	`DeferredCompensationLiabilityCurrent`	$42.50M	USD	Point-in-time
Accrued compensation	`DeferredCompensationLiabilityCurrent`	$38.67M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$77.16M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$45.28M	USD	Point-in-time
Noncontrolling interest liability	`InvestmentsPayable`	$78.00M	USD	Point-in-time
Noncontrolling interest liability	`InvestmentsPayable`	$78.00M	USD	Point-in-time
Noncontrolling interest liability	`InvestmentsPayable`	-	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$11.33M	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$14.96M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$194.69M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$167.75M	USD	Point-in-time
Convertible senior notes, net	`ConvertibleDebtNoncurrent`	$1.14B	USD	Point-in-time
Convertible senior notes, net	`ConvertibleDebtNoncurrent`	$1.13B	USD	Point-in-time
Long-term operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$226.05M	USD	Point-in-time
Long-term operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$221.50M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$9.29M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$3.93M	USD	Point-in-time
Total Liabilities	`Liabilities`	$1.53B	USD	Point-in-time
Total Liabilities	`Liabilities`	$1.56B	USD	Point-in-time
Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of June 30, 2022 and December 31, 2021	`PreferredStockValueOutstanding`	-	USD	Point-in-time
Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of June 30, 2022 and December 31, 2021	`PreferredStockValueOutstanding`	-	USD	Point-in-time
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of June 30, 2022, and December 31, 2021; 102,186,856 and 101,767,446 shares issued and outstanding as of June 30, 2022, and December 31, 2021, respectively	`CommonStockValueOutstanding`	$1.00K	USD	Point-in-time
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of June 30, 2022, and December 31, 2021; 102,186,856 and 101,767,446 shares issued and outstanding as of June 30, 2022, and December 31, 2021, respectively	`CommonStockValueOutstanding`	$1.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$1.66B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$1.70B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-4.76M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-24.26M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-1.01B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-1.36B	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$788.07M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$645.00M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$847.05M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$319.09M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$533.04M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$1.30B	USD	Point-in-time
Total Liabilities and Stockholders Equity	`LiabilitiesAndStockholdersEquity`	$2.20B	USD	Point-in-time
Total Liabilities and Stockholders Equity	`LiabilitiesAndStockholdersEquity`	$1.85B	USD	Point-in-time

Income Statement 96 line items

Line Item	Tag	Value	Unit	Period
Precision oncology testing	`RevenueFromPrecisionOncologyTesting`	$176.20M	USD	2 Qtrs
Precision oncology testing	`RevenueFromPrecisionOncologyTesting`	$72.60M	USD	1 Quarter
Precision oncology testing	`RevenueFromPrecisionOncologyTesting`	$136.33M	USD	2 Qtrs
Precision oncology testing	`RevenueFromPrecisionOncologyTesting`	$92.06M	USD	1 Quarter
Development services and other	`RevenueFromDevelopmentServices`	$19.50M	USD	1 Quarter
Development services and other	`RevenueFromDevelopmentServices`	$34.43M	USD	2 Qtrs
Development services and other	`RevenueFromDevelopmentServices`	$29.05M	USD	2 Qtrs
Development services and other	`RevenueFromDevelopmentServices`	$17.08M	USD	1 Quarter
Total revenue	`Revenues`	$205.24M	USD	2 Qtrs
Total revenue	`Revenues`	$92.10M	USD	1 Quarter
Total revenue	`Revenues`	$109.14M	USD	1 Quarter
Total revenue	`Revenues`	$170.77M	USD	2 Qtrs
Cost of precision oncology testing	`CostsOfPrecisionOncologyTesting`	$34.38M	USD	1 Quarter
Cost of precision oncology testing	`CostsOfPrecisionOncologyTesting`	$65.06M	USD	2 Qtrs
Cost of precision oncology testing	`CostsOfPrecisionOncologyTesting`	$48.48M	USD	2 Qtrs
Cost of precision oncology testing	`CostsOfPrecisionOncologyTesting`	$24.89M	USD	1 Quarter
Cost of development services and other	`CostOfDevelopmentServices`	$10.20M	USD	2 Qtrs
Cost of development services and other	`CostOfDevelopmentServices`	$2.35M	USD	1 Quarter
Cost of development services and other	`CostOfDevelopmentServices`	$3.65M	USD	2 Qtrs
Cost of development services and other	`CostOfDevelopmentServices`	$5.04M	USD	1 Quarter
Research and development expense	`ResearchAndDevelopmentExpense`	$167.21M	USD	2 Qtrs
Research and development expense	`ResearchAndDevelopmentExpense`	$63.72M	USD	1 Quarter
Research and development expense	`ResearchAndDevelopmentExpense`	$119.23M	USD	2 Qtrs
Research and development expense	`ResearchAndDevelopmentExpense`	$85.45M	USD	1 Quarter
Sales and marketing expense	`SellingAndMarketingExpense`	$47.72M	USD	1 Quarter
Sales and marketing expense	`SellingAndMarketingExpense`	$73.60M	USD	1 Quarter
Sales and marketing expense	`SellingAndMarketingExpense`	$138.03M	USD	2 Qtrs
Sales and marketing expense	`SellingAndMarketingExpense`	$82.05M	USD	2 Qtrs
General and administrative expense	`GeneralAndAdministrativeExpense`	$84.95M	USD	2 Qtrs
General and administrative expense	`GeneralAndAdministrativeExpense`	$48.38M	USD	1 Quarter
General and administrative expense	`GeneralAndAdministrativeExpense`	$116.31M	USD	2 Qtrs
General and administrative expense	`GeneralAndAdministrativeExpense`	$43.68M	USD	1 Quarter
Total costs and operating expenses	`CostsAndExpenses`	$376.27M	USD	2 Qtrs
Total costs and operating expenses	`CostsAndExpenses`	$458.90M	USD	2 Qtrs
Total costs and operating expenses	`CostsAndExpenses`	$239.47M	USD	1 Quarter
Total costs and operating expenses	`CostsAndExpenses`	$189.74M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-253.66M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-130.32M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-205.50M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-97.64M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$2.17M	USD	2 Qtrs
Interest income	`InvestmentIncomeInterest`	$2.59M	USD	2 Qtrs
Interest income	`InvestmentIncomeInterest`	$1.39M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$1.04M	USD	1 Quarter
Interest expense	`InterestExpense`	$1.29M	USD	2 Qtrs
Interest expense	`InterestExpense`	$645.00K	USD	1 Quarter
Interest expense	`InterestExpense`	$1.29M	USD	2 Qtrs
Interest expense	`InterestExpense`	$644.00K	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-533.00K	USD	2 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$378.00K	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-243.00K	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$330.00K	USD	2 Qtrs
Fair value adjustments of noncontrolling interest liability	`FairValueOptionChangesInFairValueGainLoss1`	-	USD	1 Quarter
Fair value adjustments of noncontrolling interest liability	`FairValueOptionChangesInFairValueGainLoss1`	$-99.78M	USD	1 Quarter
Fair value adjustments of noncontrolling interest liability	`FairValueOptionChangesInFairValueGainLoss1`	$-99.78M	USD	2 Qtrs
Fair value adjustments of noncontrolling interest liability	`FairValueOptionChangesInFairValueGainLoss1`	-	USD	2 Qtrs
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-352.24M	USD	2 Qtrs
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-228.99M	USD	1 Quarter
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-97.49M	USD	1 Quarter
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-204.74M	USD	2 Qtrs
Provision for income taxes	`IncomeTaxExpenseBenefit`	$83.00K	USD	1 Quarter
Provision for income taxes	`IncomeTaxExpenseBenefit`	$422.00K	USD	2 Qtrs
Provision for income taxes	`IncomeTaxExpenseBenefit`	$446.00K	USD	1 Quarter
Provision for income taxes	`IncomeTaxExpenseBenefit`	$193.00K	USD	2 Qtrs
Net loss	`ProfitLoss`	$-352.66M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-229.43M	USD	1 Quarter
Net loss	`ProfitLoss`	$-204.93M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-97.58M	USD	1 Quarter
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	-	USD	1 Quarter
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	-	USD	1 Quarter
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	-	USD	2 Qtrs
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	$2.30M	USD	2 Qtrs
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersDiluted`	$-97.58M	USD	1 Quarter
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersDiluted`	$-352.66M	USD	2 Qtrs
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersDiluted`	$-207.23M	USD	2 Qtrs
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersDiluted`	$-229.43M	USD	1 Quarter
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-207.23M	USD	2 Qtrs
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-97.58M	USD	1 Quarter
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-352.66M	USD	2 Qtrs
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-229.43M	USD	1 Quarter
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)	`EarningsPerShareBasic`	$-2.25	USD	1 Quarter
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)	`EarningsPerShareBasic`	$-2.05	USD	2 Qtrs
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)	`EarningsPerShareBasic`	$-0.96	USD	1 Quarter
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)	`EarningsPerShareBasic`	$-3.46	USD	2 Qtrs
Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)	`EarningsPerShareDiluted`	$-2.25	USD	1 Quarter
Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)	`EarningsPerShareDiluted`	$-3.46	USD	2 Qtrs
Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)	`EarningsPerShareDiluted`	$-2.05	USD	2 Qtrs
Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)	`EarningsPerShareDiluted`	$-0.96	USD	1 Quarter
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	101.95M	shares	2 Qtrs
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	101.17M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	102.05M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	101.06M	shares	2 Qtrs
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	101.17M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	101.06M	shares	2 Qtrs
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	102.05M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	101.95M	shares	2 Qtrs

Cash Flow Statement 95 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-352.66M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-229.43M	USD	1 Quarter
Net loss	`ProfitLoss`	$-204.93M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-97.58M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$15.99M	USD	2 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$10.64M	USD	2 Qtrs
Non-cash operating lease costs	`NonCashOperatingLeaseCosts`	$10.84M	USD	2 Qtrs
Non-cash operating lease costs	`NonCashOperatingLeaseCosts`	$14.20M	USD	2 Qtrs
Re-valuation of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$875.00K	USD	2 Qtrs
Re-valuation of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$3.81M	USD	2 Qtrs
Non-cash stock-based compensation	`ShareBasedCompensation`	$89.58M	USD	2 Qtrs
Non-cash stock-based compensation	`ShareBasedCompensation`	$50.34M	USD	2 Qtrs
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$1.28M	USD	2 Qtrs
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$1.28M	USD	2 Qtrs
Amortization of premium (discount) on marketable securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$-3.80M	USD	2 Qtrs
Amortization of premium (discount) on marketable securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$-6.53M	USD	2 Qtrs
Fair value adjustments of noncontrolling interest liability	`FairValueAdjustmentsOfNoncontrollingInterestLiability`	-	USD	2 Qtrs
Fair value adjustments of noncontrolling interest liability	`FairValueAdjustmentsOfNoncontrollingInterestLiability`	$-99.78M	USD	2 Qtrs
Other	`OtherNoncashIncomeExpense`	$-8.00K	USD	2 Qtrs
Other	`OtherNoncashIncomeExpense`	$-20.00K	USD	2 Qtrs
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$-2.35M	USD	2 Qtrs
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$368.00K	USD	2 Qtrs
Inventory	`IncreaseDecreaseInInventories`	$29.22M	USD	2 Qtrs
Inventory	`IncreaseDecreaseInInventories`	$3.78M	USD	2 Qtrs
Prepaid expenses and other current assets, net	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-23.67M	USD	2 Qtrs
Prepaid expenses and other current assets, net	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$3.04M	USD	2 Qtrs
Other assets, net	`IncreaseDecreaseInOtherOperatingAssets`	$-4.30M	USD	2 Qtrs
Other assets, net	`IncreaseDecreaseInOtherOperatingAssets`	$4.28M	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$11.09M	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$7.11M	USD	2 Qtrs
Accrued compensation	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$6.46M	USD	2 Qtrs
Accrued compensation	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$-3.82M	USD	2 Qtrs
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$7.30M	USD	2 Qtrs
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$15.16M	USD	2 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$-6.59M	USD	2 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$-3.03M	USD	2 Qtrs
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$5.95M	USD	2 Qtrs
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-70.00K	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-140.55M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-78.88M	USD	2 Qtrs
Purchase of marketable securities	`PaymentsToAcquireMarketableSecurities`	$126.16M	USD	2 Qtrs
Purchase of marketable securities	`PaymentsToAcquireMarketableSecurities`	$238.60M	USD	2 Qtrs
Maturity of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$418.11M	USD	2 Qtrs
Maturity of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$335.00M	USD	2 Qtrs
Purchase of non-marketable equity securities and other related investments	`PaymentsToAcquireEquitySecuritiesFvNi`	$12.75M	USD	2 Qtrs
Purchase of non-marketable equity securities and other related investments	`PaymentsToAcquireEquitySecuritiesFvNi`	$12.75M	USD	2 Qtrs
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$45.73M	USD	2 Qtrs
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$28.26M	USD	2 Qtrs
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$250.94M	USD	2 Qtrs
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$37.91M	USD	2 Qtrs
Payments made on finance lease obligations	`FinanceLeasePrincipalPayments`	$35.00K	USD	2 Qtrs
Payments made on finance lease obligations	`FinanceLeasePrincipalPayments`	$91.00K	USD	2 Qtrs
Proceeds from issuance of common stock upon exercise of stock options	`ProceedsFromStockOptionsExercised`	$5.39M	USD	2 Qtrs
Proceeds from issuance of common stock upon exercise of stock options	`ProceedsFromStockOptionsExercised`	$2.16M	USD	2 Qtrs
Proceeds from issuances of common stock under employee stock purchase plan	`ProceedsFromStockPlans`	$5.40M	USD	2 Qtrs
Proceeds from issuances of common stock under employee stock purchase plan	`ProceedsFromStockPlans`	$5.74M	USD	2 Qtrs
Taxes paid related to net share settlement of restricted stock units	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$74.96M	USD	2 Qtrs
Taxes paid related to net share settlement of restricted stock units	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$2.18M	USD	2 Qtrs
Joint Venture Acquisition	`PaymentsForJointVentureAcquisitionFinancingActivities`	-	USD	2 Qtrs
Joint Venture Acquisition	`PaymentsForJointVentureAcquisitionFinancingActivities`	$177.78M	USD	2 Qtrs
Payment of offering costs related to borrowings on convertible senior notes	`PaymentsOfDebtIssuanceCosts`	$784.00K	USD	2 Qtrs
Payment of offering costs related to borrowings on convertible senior notes	`PaymentsOfDebtIssuanceCosts`	-	USD	2 Qtrs
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-65.04M	USD	2 Qtrs
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-172.10M	USD	2 Qtrs
Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-2.21M	USD	2 Qtrs
Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-1.08M	USD	2 Qtrs
Net (decrease) increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$105.93M	USD	2 Qtrs
Net (decrease) increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-276.95M	USD	2 Qtrs
Cash, cash equivalents and restricted cashBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$492.29M	USD	Point-in-time
Cash, cash equivalents and restricted cashBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$215.34M	USD	Point-in-time
Cash, cash equivalents and restricted cashBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$938.90M	USD	Point-in-time
Cash, cash equivalents and restricted cashBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$832.98M	USD	Point-in-time
Cash, cash equivalents and restricted cashEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$492.29M	USD	Point-in-time
Cash, cash equivalents and restricted cashEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$215.34M	USD	Point-in-time
Cash, cash equivalents and restricted cashEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$938.90M	USD	Point-in-time
Cash, cash equivalents and restricted cashEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$832.98M	USD	Point-in-time
Operating lease liabilities arising from obtaining right-of-use assets	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$170.91M	USD	2 Qtrs
Operating lease liabilities arising from obtaining right-of-use assets	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$4.07M	USD	2 Qtrs
Purchase of property and equipment included in accounts payable and accrued expenses	`CapitalExpendituresIncurredButNotYetPaid`	$10.29M	USD	2 Qtrs
Purchase of property and equipment included in accounts payable and accrued expenses	`CapitalExpendituresIncurredButNotYetPaid`	$16.90M	USD	2 Qtrs
Issuance costs related to purchase of non-marketable equity and other related investments included in accounts payable and accrued expenses	`EquitySecuritiesFVNIIncurredButNotYetPaid`	$587.00K	USD	2 Qtrs
Issuance costs related to purchase of non-marketable equity and other related investments included in accounts payable and accrued expenses	`EquitySecuritiesFVNIIncurredButNotYetPaid`	-	USD	2 Qtrs
Property and equipment acquired under finance leases	`PropertyPlantAndEquipmentAcquiredUnderFinanceLeases`	$236.00K	USD	2 Qtrs
Property and equipment acquired under finance leases	`PropertyPlantAndEquipmentAcquiredUnderFinanceLeases`	-	USD	2 Qtrs
Tender offer issued in connection with the Joint Venture Acquisition and acquisition related costs	`NoncashTenderOfferIssued`	-	USD	2 Qtrs
Tender offer issued in connection with the Joint Venture Acquisition and acquisition related costs	`NoncashTenderOfferIssued`	$9.69M	USD	2 Qtrs
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$938.59M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$215.17M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$492.20M	USD	Point-in-time
Restricted cash included in other assets, net	`RestrictedCashNoncurrent`	$315.00K	USD	Point-in-time
Restricted cash included in other assets, net	`RestrictedCashNoncurrent`	$170.00K	USD	Point-in-time
Total cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$492.29M	USD	Point-in-time
Total cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$215.34M	USD	Point-in-time
Total cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$938.90M	USD	Point-in-time
Total cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$832.98M	USD	Point-in-time

Stockholders Equity 44 line items

Line Item	Tag	Value	Unit	Period
Adjustment of redeemable noncontrolling interest	`ReclassificationsOfTemporaryToPermanentEquity`	$-2.30M	USD	2 Qtrs
Beginning balance	`StockholdersEquity`	$788.07M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$645.00M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$847.05M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$319.09M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$533.04M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$1.30B	USD	Point-in-time
Issuance of common stock upon exercise of stock options (in shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	156,015.00	shares	2 Qtrs
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$1.19M	USD	1 Quarter
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$5.39M	USD	2 Qtrs
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$926.00K	USD	1 Quarter
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$2.16M	USD	2 Qtrs
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueExerciseOfWarrants`	$26.00K	USD	2 Qtrs
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueExerciseOfWarrants`	$8.00K	USD	2 Qtrs
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueExerciseOfWarrants`	$13.00K	USD	1 Quarter
Common stock issued under employee stock purchase plan	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$5.40M	USD	1 Quarter
Common stock issued under employee stock purchase plan	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$5.74M	USD	2 Qtrs
Common stock issued under employee stock purchase plan	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$5.40M	USD	2 Qtrs
Common stock issued under employee stock purchase plan	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$5.74M	USD	1 Quarter
Taxes paid related to net share settlement of restricted stock units	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$2.18M	USD	2 Qtrs
Taxes paid related to net share settlement of restricted stock units	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$1.22M	USD	1 Quarter
Taxes paid related to net share settlement of restricted stock units	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$74.96M	USD	2 Qtrs
Taxes paid related to net share settlement of restricted stock units	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$1.38M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$50.34M	USD	2 Qtrs
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$89.58M	USD	2 Qtrs
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$34.51M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$25.54M	USD	1 Quarter
Tender offer issued in connection with the Joint Venture Acquisition and acquisition related costs	`AdjustmentsToAdditionalPaidInCapitalTenderOfferIssued`	$9.83M	USD	2 Qtrs
Tender offer issued in connection with the Joint Venture Acquisition and acquisition related costs	`AdjustmentsToAdditionalPaidInCapitalTenderOfferIssued`	$9.83M	USD	1 Quarter
Adjustment of redeemable noncontrolling interest	`ReclassificationsOfTemporaryToPermanentEquity`	$-2.30M	USD	2 Qtrs
Other comprehensive loss, net of tax impact	`OtherComprehensiveIncomeLossNetOfTax`	$-871.00K	USD	1 Quarter
Other comprehensive loss, net of tax impact	`OtherComprehensiveIncomeLossNetOfTax`	$-5.95M	USD	1 Quarter
Other comprehensive loss, net of tax impact	`OtherComprehensiveIncomeLossNetOfTax`	$-19.50M	USD	2 Qtrs
Other comprehensive loss, net of tax impact	`OtherComprehensiveIncomeLossNetOfTax`	$-2.66M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-352.66M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-229.43M	USD	1 Quarter
Net loss	`ProfitLoss`	$-204.93M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-97.58M	USD	1 Quarter
Ending balance	`StockholdersEquity`	$788.07M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$645.00M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$847.05M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$319.09M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$533.04M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$1.30B	USD	Point-in-time

Comprehensive Income 28 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-352.66M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-229.43M	USD	1 Quarter
Net loss	`ProfitLoss`	$-204.93M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-97.58M	USD	1 Quarter
Unrealized loss on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-1.58M	USD	2 Qtrs
Unrealized loss on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-4.53M	USD	1 Quarter
Unrealized loss on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-17.29M	USD	2 Qtrs
Unrealized loss on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-878.00K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$7.00K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$-1.08M	USD	2 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$-2.21M	USD	2 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$-1.42M	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-871.00K	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-5.95M	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-19.50M	USD	2 Qtrs
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-2.66M	USD	2 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-98.45M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-372.16M	USD	2 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-207.60M	USD	2 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-235.38M	USD	1 Quarter
Comprehensive loss attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	-	USD	1 Quarter
Comprehensive loss attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	$2.30M	USD	2 Qtrs
Comprehensive loss attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	-	USD	1 Quarter
Comprehensive loss attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	-	USD	2 Qtrs
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-98.45M	USD	1 Quarter
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-209.90M	USD	2 Qtrs
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-372.16M	USD	2 Qtrs
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-235.38M	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.